Human health risk assessments for three neuropharmaceutical compounds in surface waters

Regulatory Toxicology and Pharmacology

Volumn 50, Issue 3, 2008, Pages 420-427

  Bercu, Joel P ^a   Parke, Neil J ^a   Fiori, Janice M ^a   Meyerhoff, Roger D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

CSAF; Fish consumption; Human health; Pharmaceuticals; PhATE ; PNEC; Risk assessment; Water

Indexed keywords

ATOMOXETINE; DULOXETINE; OLANZAPINE; PLACEBO; SURFACE WATER;

ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; DRUG SAFETY; DRUG STRUCTURE; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HEALTH HAZARD; HUMAN; MAJOR DEPRESSION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; UNITED STATES;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG RESIDUES; ENVIRONMENTAL EXPOSURE; FISHES; FOOD ANALYSIS; FORECASTING; HUMANS; MODELS, STATISTICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PROPYLAMINES; RISK ASSESSMENT; THIOPHENES; UNITED STATES; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

EID: 41949098620     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2008.01.014     Document Type: Article

References (39)

1. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., Duplessie B.M., Hayes E.P., Mastrocco F.J., Parke N.J., Rader J.C., Samuelian J.H., and Schwab B.W. Screening analysis of human pharmaceutical compounds in US surface waters. Environ. Sci. Technol. 38 (2004) 838-849
2. Beasley Jr. C.M., Hamilton S.H., and Crawford A.M. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol. 7 (1997) 125-137
3. Beasley Jr. C.M., Sanger T., Satterlee W., Tollefson G., Tran P., and Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124 (1996) 159-167
4. Christensen F.M. Pharmaceuticals in the environment-a human risk?. Regul. Toxicol. Pharmacol. 28 (1998) 212-221
5. Clarke D.O., Connelly C.S., Hall R.L., Leedle R.A., Miller E.M., Williams J.M., Sarazan R.D., Ponsler G.D., Sauer J.M., and Tizzano J.P. Nonclinical pediatric testing of tomoxetine: toxicity study in young beagle dogs. Neurotoxicol. Teratol. 23 (2001) 294-295
6. Cowan C.E., Larson R.J., Feijtel T.C.J., and Rapaport R.A. An improved model for predicting the fate of consumer product chemicals in wastewater treatment plants. Water Res. 27 (1993) 561-573
7. Dorne J.L., Walton K., and Renwick A.G. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 43 (2005) 203-216
8. Dorne J.L., Walton K., Slob W., and Renwick A.G. Human variability to polymorphic CYP2D6 metabolism: Is the kinetic default uncertainty factor inadequate?. Food Chem. Toxicol. 40 (2002) 1633-1656
9. Dourson M.L., Andersen M.E., Erdreich L.S., and MacGregor J.A. Using human data to protect the public's health. Regul. Toxicol. Pharmacol. 33 (2001) 234-256
10. Eli Lilly and Company, 2004. Olanzapine. Material Safety Data Sheet. Eli Lilly and Company. Available from: .
11. Eli Lilly and Company, 2005a. Atomoxetine Hydrochloride. Material Safety Data Sheet. Eli Lilly and Company. Available from: .
12. Eli Lilly and Company, 2005b. Duloxetine Hydrochloride. Material Safety Data Sheet. Eli Lilly and Company. Available from: .
13. ® (olanzapine for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company. Available from: .
14. ® (atomoxetine HCI) [package insert]. Indianapolis, IN: Eli Lilly and Company. Available from: .
15. ® (duloxetine hydrochloride) delayed-release capsules [package insert]. Indianapolis, IN: Eli Lilly and Company. Available from: .
16. Goldstein D.J., Mallinckrodt C., Lu Y., and Demitrack M.A. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry 63 (2002) 225-231
17. TM, January 2007.
18. IPCS (International Programme on Chemical Safety), 1999. Principles for the assessment of risks to human health from exposure to chemicals. EHC 210. World Health Organization, Geneva (Switzerland). Available from: .
19. IPCS (International Programme on Chemical Safety), 2005. Chemical-specific adjustment factors for interspecies difference and human variability: Guidance document for use of data in dose/concentration-response assessment. Harmonization Project Document No. 2. World Health Organization, Geneva (Switzerland). Available from: .
20. Johnson A.C., and Sumpter J.P. Removal of endocrine-disrupting chemicals in activated sludge treatment works. Environ. Sci. Technol. 35 (2001) 4697-4703
21. Jones O.A., Lester J.N., and Voulvoulis N. Pharmaceuticals: a threat to drinking water?. Trends Biotechnol. 23 (2005) 163-167
22. Kassahun K., Mattiuz E., Nyhart Jr. E., Obermeyer B., Gillespie T., Murphy A., Goodwin R.M., Tupper D., Callaghan J.T., and Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 1997 (1997) 81-93
23. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., and Buxton H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: A national reconnaissance. Environ. Sci. Technol. 36 (2002) 1202-1211
24. Lantz R.J., Gillespie T.A., Rash T.J., Kuo F., Skinner M., Kuan H.Y., and Knadler M.P. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. 31 (2003) 1142-1150
25. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., Spencer, T., 2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108, E83. Available from: .
26. Naumann B.D., Silverman K.C., Dixit R., Faria E.C., and Sargent E.V. Case studies of categorical data-derived adjustment factors. Hum. Ecol. Risk. Assess. 7 (2001) 61-105
27. Sauer J.M., Ponsler G.D., Mattiuz E.L., Long A.J., Witcher J.W., Thomasson H.R., and Desante K.A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 31 (2003) 98-107
28. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., and Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum. Ecol. Risk. Assess. 8 (2002) 657-680
29. Schwab B.W., Hayes E.P., Fiori J.M., Mastrocco F.J., Roden N.M., Cragin D., Meyerhoff R.D., D'Aco V.J., and Anderson P.D. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul. Toxicol. Pharmacol. 42 (2005) 296-312
30. Thase M.E., Tran P.V., Wiltse C., Pangallo B.A., Mallinckrodt C., and Detke M.J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol. 25 (2005) 132-140
31. Tizzano J.P., Childers D.H., Griffey K.I., Hoog J.F., Johnson J.A., Kimball J.R., Knapp R.L., Wakefield A.E., Fisher L.F., Seyler D.E., Swisher D.K., Jensen C.B., Ponsler G.D., Sauer J.-M., and Clarke D.O. Nonclinical pediatric testing of tomoxetine: toxicity, reproduction/fertility and neurobehavioural studies in young Fischer 344 rats. Neurotoxicol. Terat. 23 (2001) 295
32. USEPA (U.S. Environmental Protection Agency), 2000. Methodology for deriving ambient water quality criteria for the protection of human health (2000). EPA-822-B-00-004. Office of Science and Technology, Office of Water, Washington (DC). Available from: .
33. USEPA (U.S. Environmental Protection Agency), 2002a. A review of the reference dose and reference concentration processes (Final report). EPA/630/P-02/002F. Risk Assessment Forum, Washington (DC). Available from: .
34. USEPA (U.S. Environmental Protection Agency), 2002b. Estimated per capita fish consumption in the United States. EPA/821/C-02/003. Office of Water. Washington, DC. Available from: .
35. USFDA (US Food and Drug Administration), 1996. Zyprexa (Olanzapine) [Summary Basis of Approval]. Center for Drug Evaluation and Research, Rockville (MD).
36. USFDA (US Food and Drug Administration), 1998. Guidance for industry environmental assessment of human drug and biologics applications. Center for Drug Evaluation and Research, Rockville (MD). Available from: .
37. USFDA (US Food and Drug Administration), 2002. Strattera (Atomoxetine Hydrochloride) capsules [Summary Basis of Approval]. Center for Drug Evaluation and Research, Rockville (MD). Available from: .
38. USFDA (US Food and Drug Administration), 2004. Cymbalta (Duloxetine Hydrochloride) capsules [Summary Basis of Approval]. Center for Drug Evaluation and Research, Rockville (MD). Available from: .
39. Webb S., Ternes T., Gibert M., and Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol. Lett. 142 (2003) 157-167